Quantum Biopharma Ltd. QNTM
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Quantum Biopharma Ltd. (QNTM) is a healthcare company listed in the US with a market value of about $10M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -59%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
About Quantum Biopharma
Quantum Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 4 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | — | — | — | $197860 |
| Net income | -$24M | -$35M | -$32M | -$39M |
| Free cash flow | -$28M | -$21M | -$19M | — |
| EPS (diluted) | $-3.67 | $-5.49 | $-4.95 | $-6.09 |
| Net margin | — | — | — | -19776.4% |
| ROIC | -71.0% | -49.2% | -66.8% | -49.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $12.22, 659% above the current price; targets range from $12.22 to $12.22; the consensus rating is “none”; expected EPS is $-2.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Quantum Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Quantum Biopharma pay a dividend?
Not currently.
Is Quantum Biopharma a good stock to buy?
We do not give buy or sell advice. Quantum Biopharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.